Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Novavax has received $1.6bn under the US Government’s Operation Warp Speed (OWS) programme to support the development and manufacturing of its Covid-19 vaccine candidate.
Named NVX‑CoV2373, the vaccine is made up of a stable, prefusion protein created using the company’s nanoparticle technology and includes its Matrix‑M adjuvant.
The company will use the funding for late-stage clinical development, large-scale manufacturing and to deliver 100 million doses of NVX‑CoV2373 by late 2020.
Novavax president and CEO Stanley Erck said: “The pandemic has caused an unprecedented public health crisis, making it more important than ever.